Daishin Balance No.6 Special Purpose Acquisition Co. Ltd (307750) - Total Liabilities

Latest as of September 2025: ₩79.37 Billion KRW ≈ $53.79 Million USD

Based on the latest financial reports, Daishin Balance No.6 Special Purpose Acquisition Co. Ltd (307750) has total liabilities worth ₩79.37 Billion KRW (≈ $53.79 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Daishin Balance No.6 Special Purpose Acquisition Co. Ltd - Total Liabilities Trend (2020–2024)

This chart illustrates how Daishin Balance No.6 Special Purpose Acquisition Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. See how liquid is Daishin Balance No.6 Special Purpose Acq's working capital to evaluate short-term liquidity relative to the company's equity base.

Daishin Balance No.6 Special Purpose Acquisition Co. Ltd Competitors by Total Liabilities

The table below lists competitors of Daishin Balance No.6 Special Purpose Acquisition Co. Ltd ranked by their total liabilities.

Company Country Total Liabilities
ST Dupont
PA:DPT
France €30.70 Million
Daehan Synthet
KO:003830
Korea ₩127.57 Billion
Interlink Communication Public Company Limited
BK:ILINK
Thailand ฿5.15 Billion
Holland Colours NV
AS:HOLCO
Netherlands €14.97 Million
AMCON Distributing Company
NYSE MKT:DIT
USA $282.10 Million
Talga Group Ltd
F:TGX
Germany €5.87 Million
Blue Cap AG
XETRA:B7E
Germany €112.79 Million
JMC Electronics Co Ltd
TW:6552
Taiwan NT$1.58 Billion

Liability Composition Analysis (2020–2024)

This chart breaks down Daishin Balance No.6 Special Purpose Acquisition Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Daishin Balance No.6 Special Purpose Acq worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 1.16 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.80 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.45 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Daishin Balance No.6 Special Purpose Acquisition Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Daishin Balance No.6 Special Purpose Acquisition Co. Ltd (2020–2024)

The table below shows the annual total liabilities of Daishin Balance No.6 Special Purpose Acquisition Co. Ltd from 2020 to 2024.

Year Total Liabilities Change
2024-12-31 ₩114.85 Billion
≈ $77.83 Million
-10.02%
2023-12-31 ₩127.65 Billion
≈ $86.50 Million
+23.00%
2022-12-31 ₩103.77 Billion
≈ $70.33 Million
+335.32%
2021-12-31 ₩23.84 Billion
≈ $16.15 Million
-6.78%
2020-12-31 ₩25.57 Billion
≈ $17.33 Million
--

About Daishin Balance No.6 Special Purpose Acquisition Co. Ltd

KQ:307750 Korea Drug Manufacturers - General
Market Cap
$81.27 Million
₩119.92 Billion KRW
Market Cap Rank
#20091 Global
#1064 in Korea
Share Price
₩2390.00
Change (1 day)
-6.46%
52-Week Range
₩2315.00 - ₩5540.00
All Time High
₩22045.88
About

KUKJEON PHARMACEUTICAL Co., Ltd operates as a chemical total solutions provider in South Korea. It provides various chemical-based products and services; and after-sales services, such as research and development, production, quality control, and DMF services. The company manufactures active pharmaceutical ingredients; and offers molecular design and technical support. It develops electronic mate… Read more